Barinthus Biotherapeutics (BRNS) Income towards Parent Company (2020 - 2026)

Barinthus Biotherapeutics has reported Income towards Parent Company for 7 years, with the latest figure at -$5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 71.85% year-over-year to -$5.5 million; the trailing twelve-month figure through Mar 2026 stood at -$52.3 million (up 19.88% YoY), and the FY2025 full-year result was -$66.5 million, down 8.62% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$5.5 million, up from -$11.1 million in the prior quarter.
• The five-year high for Income towards Parent Company was $15.7 million in Q2 2022, with the low at -$23.8 million in Q2 2023.
• Historically, Income towards Parent Company has averaged -$11.8 million across 5 years, with a median of -$15.5 million in 2024.
• Annual changes were most pronounced in 2022 — Income towards Parent Company soared 248.69% — and 2023, when it sank 807.96%.
• Barinthus Biotherapeutics' Income towards Parent Company stood at -$21.2 million in 2022, then grew by 18.3% to -$17.3 million in 2023, then decreased by 19.09% to -$20.6 million in 2024, then jumped by 46.08% to -$11.1 million in 2025, then surged by 50.16% to -$5.5 million in 2026.
• The last three Income towards Parent Company figures came in at -$5.5 million (Q1 2026), -$11.1 million (Q4 2025), and -$14.6 million (Q3 2025), per Business Quant data.